Trafermin
- Generic Name
- Trafermin
- Drug Type
- Biotech
- CAS Number
- 131094-16-1
- Unique Ingredient Identifier
- 333OX80X87
- Indication
Investigated for use/treatment in coronary artery disease, peripheral vascular disease, periodontal disease, bone fractures, entero-related fistulae, and diabetic foot ulcers.
The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study
Phase 3
Completed
- Conditions
- Diabetic Foot Ulcer of Neuropathic Origin
- Interventions
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Olympus Biotech Corporation
- Target Recruit Count
- 201
- Registration Number
- NCT01217463
The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study
Phase 3
Completed
- Conditions
- Diabetic Foot Ulcer of Neuropathic Origin
- Interventions
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Olympus Biotech Corporation
- Target Recruit Count
- 207
- Registration Number
- NCT01217476
- Locations
- 🇭🇺
LL, Budapest, Hungary
🇭🇺PF, Budapest, Hungary
🇸🇪EL, Malmö, Sweden
A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)
- First Posted Date
- 2009-11-18
- Last Posted Date
- 2013-10-21
- Lead Sponsor
- Kaken Pharmaceutical
- Target Recruit Count
- 25
- Registration Number
- NCT01015404
- Locations
- 🇯🇵
Kaken Investigational Site 2, Matsudo, Japan
🇯🇵Kaken Investigational Site 1, Sapporo, Japan
🇯🇵Kaken Investigational Site 4, Shinjuku-ku, Japan
Phase 3 Clinical Trial of Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2(Trafermin)
Phase 3
Completed
- Conditions
- PeriodontitisAlveolar Bone LossPeriodontal Attachment Loss
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2012-06-15
- Lead Sponsor
- Kaken Pharmaceutical
- Target Recruit Count
- 328
- Registration Number
- NCT00734708
- Locations
- 🇯🇵
Kaken Investigational Site, Tokushima, Japan
Trial in Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2
Phase 2
Completed
- Conditions
- Periodontitis
- Interventions
- First Posted Date
- 2007-08-10
- Last Posted Date
- 2007-08-10
- Lead Sponsor
- Kaken Pharmaceutical
- Target Recruit Count
- 91
- Registration Number
- NCT00514657
A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in Japan
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2008-02-05
- Lead Sponsor
- Kaken Pharmaceutical
- Target Recruit Count
- 267
- Registration Number
- NCT00199290
- Locations
- 🇯🇵
Kaken Investigational Site, Tokushima, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath